Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label bortezomib study in androgen-independent prostate carcinoma after prior chemotherapy
2006-001933-16Phase 2Active
- Sponsor
- Christos N. Papandreou
- Start
- Oct 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in castration-resistant prostate cancer (CRPC), sponsored by Christos N. Papandreou. Primary endpoints: Objective response rate and PSA response rate. Started Oct 2006; status: active.
02
Drugs
bortezomib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2006-001933-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001933-16.